Benefits and potential harms of human papillomavirus (HPV)‐based cervical cancer screening: A real‐world comparison of HPV testing versus cytology
Abstract
Introduction: Human papillomavirus (HPV) testing as the primary cervical cancer screening method is implemented in several countries. We report data from the first round of a large Danish pilot implementation of HPV‐based screening. Our aim was to compare colposcopy referrals, detection of high‐grade cervical intraepithelial neoplasia (CIN) and cervical cancer, and positive predictive value (PPV) of colposcopy referral in HPV vs cytology‐based screening. Material and methods: From May 2017 to October 2018, women aged 30‐59 years attending cervical cancer screening in the uptake area of the Department of Pathology, Vejle Hospital, Region of Southern Denmark were screened by primary HPV testing (n = 16 067) or primary cytology (n = 23 981) depending on municipality of residence. In the HPV group, women with HPV16/18, or other high‐risk HPV types and abnormal cytology, were referred to immediate colposcopy. Women with other high‐risk HPV types and normal cytology were invited for repeat screening with HPV test and cytology after 12 months. From a nationwide pathology register, we obtained information on screening results and subsequent histological diagnoses during up to 2.9 years after the first screen. PPVs included diagnoses within 1 year after referral. Results: In the HPV group, 3.7% were referred to immediate colposcopy and 2.8% were referred at the 12‐month repeat screening. The total referral to colposcopy was higher in the HPV (6.6%) than cytology group (2.1%) (age‐adjusted relative referral = 3.05, 95% confidence interval [CI] 2.75‐3.38). The detection of CIN3+ was higher in the HPV (1.5%) than the cytology group (0.8%) (age‐adjusted relative detection = 1.88, 95% CI 1.56‐2.28). The probability of CIN3+ among women referred to colposcopy (= PPV) was lower in the HPV (21.1%; 95% CI 18.7%‐23.7%) than the cytology group (34.6%; 95% CI 30.7%‐38.9%). In the HPV group, the PPV was lower among women referred at repeat screening (12.1%) than among women referred immediately (27.8%). Conclusions: Compared with cytology‐based screening, HPV‐based screening provided a 90% increased CIN3+ detection at the cost of a threefold increase in colposcopy referrals, when considering complete data from the prevalence round. Our findings support implementation of HPV‐based screening in Denmark, but modifications of screening algorithms may be warranted to decrease unnecessary colposcopy referrals.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HPV DNA testing is more sensitive than cytology in detecting precancerous lesions and cervical cancers.
“Numerous studies affirm that HPV DNA testing is more sensitive than cytology in detecting precancerous lesions and cervical cancers [21, 22, 23] and any HPV DNA test is better than none.”
From Comparative analysis of SD biosensor standard™ M10 HPV and seegene anyplex™ II HPV HR for detecting high-risk human papillomavirus: a concordance study (2025) · cites this paper as [21]
Cites
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810 · see citing works
Ogilvie, G. S., Krajden, M., van Niekerk, D., Smith, L. W., Cook, D., Ceballos, K., Lee, M., Gentile, L., Gondara, L., Elwood‐Martin, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30454 · Cited by 101 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Jerip, A. R., Noni, V., Anthony, V. K., Bong, A. C. S., Adam, J., & Tan, C. S. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10714-y · Cited by 1 · see citing works
“Numerous studies affirm that HPV DNA testing is more sensitive than cytology in detecting precancerous lesions and cervical cancers [21, 22, 23] and any HPV DNA test is better than none.”
- Authors
- Thomsen, L. T., Kjær, S. K., Munk, C., Ørnskov, D., & Waldstrøm, M.
- Affiliations
- Danish Cancer Society (DK)
- Copenhagen University Hospital (DK)
- Vejle Sygehus (DK)
- University of Southern Denmark (DK)
- Corresponding author
- Thomsen, Louise T.
- Venue
- Acta Obstetricia et Gynecologica Scandinavica
- Publisher
- Wiley
- Published
- 2021-03
- Volume
- 100
- Issue
- 3
- Pages
- 394-402
- ISSN
- 0001-6349 (ISSN-L)
- 1600-0412
- OpenAlex
- W3128962941
- Cited by
- 36
- References
- 2
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 1
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Obstetricia Et Gynecologica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Lundbeckfonden (R287‐2018‐1454)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Keywords
- HPV testing, cervical cancer screening, cytology, colposcopy referral, positive predictive value, cervical intraepithelial neoplasia, CIN3+ detection, HPV 16/18, repeat screening, screening program implementation, screening uptake, cervical cancer incidence
- MeSH terms
- Adult, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Colposcopy, Cytological Techniques, Denmark, Female, Humans, Mass Screening, Middle Aged, Predictive Value of Tests, Referral and Consultation, Registries, Vaginal Smears, Papillomavirus Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review